ABSTRACT
BACKGROUND AND PURPOSE: (-)-Englerin A (EA) is a potent cytotoxic agent against renal carcinoma cells. It achieves its effects by activation of transient receptor potential canonical (TRPC)4/TRPC1 heteromeric channels. It is also an agonist at channels formed by the related protein, TRPC5. Here, we sought an EA analogue, which might enable a better understanding of these effects of EA. EXPERIMENTAL APPROACH: An EA analogue, A54, was synthesized by chemical elaboration of EA. The effects of EA and A54 on the activity of human TRPC4 or TRPC5 channels overexpressed on A498 and HEK 293 cells were investigated, firstly, by measuring intracellular Ca2+ and, secondly, current using whole-cell patch clamp recordings. KEY RESULTS: A54 had weak or no agonist activity at endogenous TRPC4/TRPC1 channels in A498 cells or TRPC4 or TRPC5 homomeric channels overexpressed in HEK 293 cells. A54 strongly inhibited EA-mediated activation of TRPC4/TRPC1 or TRPC5 and weakly inhibited activation of TRPC4. Studies of TRPC5 showed that A54 shifted the EA concentration-response curve to the right without changing its slope, consistent with competitive antagonism. In contrast, Gd3+ -activated TRPC5 or sphingosine-1-phosphate-activated TRPC4 channels were not inhibited but potentiated by A54. A54 did not activate TRPC3 channels or affect the activation of these channels by the agonist 1-oleoyl-2-acetyl-sn-glycerol. CONCLUSIONS AND IMPLICATIONS: This study has revealed a new tool compound for EA and TRPC1/4/5 channel research, which could be useful for characterizing endogenous TRPC1/4/5 channels and understanding EA-binding sites and their physiological relevance.
Subject(s)
Membrane Potentials/physiology , Sesquiterpenes, Guaiane/antagonists & inhibitors , TRPC Cation Channels/physiology , Calcium/metabolism , Cell Line, Tumor , Cells, Cultured , Diglycerides/pharmacology , Drug Synergism , Gadolinium/pharmacology , Humans , Lysophospholipids/pharmacology , Sesquiterpenes, Guaiane/pharmacology , Sphingosine/analogs & derivatives , Sphingosine/pharmacologyABSTRACT
Current therapies for common types of cancer such as renal cell cancer are often ineffective and unspecific, and novel pharmacological targets and approaches are in high demand. Here we show the unexpected possibility for the rapid and selective killing of renal cancer cells through activation of calcium-permeable nonselective transient receptor potential canonical (TRPC) calcium channels by the sesquiterpene (-)-englerinâ A. This compound was found to be a highly efficient, fast-acting, potent, selective, and direct stimulator of TRPC4 and TRPC5 channels. TRPC4/5 activation through a high-affinity extracellular (-)-englerinâ A binding site may open up novel opportunities for drug discovery aimed at renal cancer.
Subject(s)
Sesquiterpenes, Guaiane/chemistry , TRPC Cation Channels/agonists , Calcium/metabolism , Cell Line, Tumor , Cell Survival/drug effects , HEK293 Cells , HT29 Cells , Humans , Sesquiterpenes, Guaiane/metabolism , Sesquiterpenes, Guaiane/pharmacology , Stereoisomerism , TRPC Cation Channels/genetics , TRPC Cation Channels/metabolismABSTRACT
We report on a compact Nd:YAG amplifier emitting a maximum pulse energy of 14 mJ. By amplifying a passively Q-switched oscillator (M(2)<1.2) a good beam quality of M(2) approximately 1.7 was achieved. The amplifier is diode pumped by an 8 bar diode stack of 800 W power and a nonimaging optic. This optic homogenizes the pump light and transfers it into a 5 mm diameter core doped rod with a centrally neodymium doped region of 3 mm and a samarium doped YAG cladding. We show that this cladding reduces parasitic effects in the laser rod compared to an undoped YAG cladding. Finally, we compare the compact amplifier with an amplifier, which is mode selectively pumped by a fiber coupled pump diode.
ABSTRACT
Human Immune Deficiency Virus-1 (HIV-1) infection can induce severe and debilitating neurological problems, including behavioral abnormalities, motor dysfunction, and dementia. HIV can persistently infect astrocytes, during which viral accessory proteins are produced that are unaffected by current antiretroviral therapy. The effect of these proteins on astrocyte function remains unknown. Astrocytes are the predominant cells within the brain; thus, disruption of astrocyte function could influence the neuropathogenesis of HIV infection. To explore further these effects, we constitutively expressed HIV-Tat protein in astrocytes. Since the nuclear presence of Tat protein leads to alteration of host gene expression, we further analyzed the effects of Tat on host gene transcripts. Endothelin-1 (ET-1) was a significantly elevated transcript as verified by reverse transcription-polymerase chain reaction (RT-PCR), and it was subsequently released extracellularly in Tat-expressing and HIV-infected astrocytes. ET-1 expression was also prominent in reactive astrocytes and neurons in brain tissues from basal ganglia and frontal lobes of HIV encephalitic patients. HIV-Tat regulated ET-1 at the transcriptional level through NF-kappaB (NF-kappaB)-responsive sites in the ET-1 promoter. Intriguingly, simvastatin (10 microM) down-regulated HIV-Tat-induced ET-1 and also inhibited activation of NF-kappaB in astrocytes. Our findings suggest that ET-1 may be critical in mediating the neuropathogenesis of HIV dementia and that statins may have therapeutic potential in these patients.